Trial · NCT01357239
Results by group185
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 185
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the Aberrant Behavior Checklist-Community Edition (ABC-CFX) Total Score in Stratum I Patients Exposed to AFQ056 100 mg Bid | AFQ056 100 mg Bid | 8.6 | Standard Error 4.48 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the Aberrant Behavior Checklist-Community Edition (ABC-CFX) Total Score in Stratum I Patients Exposed to AFQ056 100 mg Bid | Placebo | -9.4 | Standard Error 3.88 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum II Patients Exposed to All 3 Doses of AFQ056 | AFQ056 25 mg Bid | -6.8 | Standard Error 3.88 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum II Patients Exposed to All 3 Doses of AFQ056 | AFQ056 50 mg Bid | -2.8 | Standard Error 4.07 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum II Patients Exposed to All 3 Doses of AFQ056 | AFQ056 100 mg Bid | -5.7 | Standard Error 4.06 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum II Patients Exposed to All 3 Doses of AFQ056 | Placebo | -3.5 | Standard Error 4.30 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum I Patients Exposed to the Two Lower Doses of AFQ056 (25 mg Bid and 50 mg Bid) | AFQ056 25 mg Bid | -11.8 | Standard Error 6.43 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum I Patients Exposed to the Two Lower Doses of AFQ056 (25 mg Bid and 50 mg Bid) | AFQ056 50 mg Bid | -3.4 | Standard Error 7.40 | Score | |
| Change From Baseline in Behavioral Symptoms of Fragile X Syndrome Using the ABC-CFX Total Score in Stratum I Patients Exposed to the Two Lower Doses of AFQ056 (25 mg Bid and 50 mg Bid) | Placebo | -9.4 | Standard Error 3.88 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum I Patients | AFQ056 25 mg Bid | 3.3 | Standard Error 0.30 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum I Patients | AFQ056 50 mg Bid | 3.8 | Standard Error 0.34 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum I Patients | AFQ056 100 mg Bid | 3.5 | Standard Error 0.22 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum I Patients | Placebo | 3.1 | Standard Error 0.18 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum II Patients | AFQ056 25 mg Bid | 3.5 | Standard Error 0.19 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum II Patients | AFQ056 50 mg Bid | 3.2 | Standard Error 0.20 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum II Patients | AFQ056 100 mg Bid | 3.5 | Standard Error 0.20 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression- Improvement (CGI-I) Scale in Stratum II Patients | Placebo | 3.4 | Standard Error 0.21 | Score | |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression-Improvement (CGI-I) Scale in Stratum I | AFQ056 25 mg Bid | 1 (Very much improved) | 1 | 0.30 | Participants |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression-Improvement (CGI-I) Scale in Stratum I | AFQ056 50 mg Bid | 1 (Very much improved) | 0 | 0.34 | Participants |
| Global Improvement of Symptoms in Fragile X Using the Clinical Global Impression-Improvement (CGI-I) Scale in Stratum I | AFQ056 100 mg Bid | 1 (Very much improved) | 0 | 0.22 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01357239/results